HERG Screening Market

HERG Screening Market Research, 2034

HERG Screening Market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 13.7% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 1.7 billion and is projected to reach USD 7.1 billion by the completion of 2034.

HERG screening refers to an essential component in drug development, which serves to evaluate the cardiotoxicity of a compound. The HERG gene includes a potassium ion channel which is crucial for regulating cardiac electrical activity. Certain drugs have the potential to cause fatal ventricular arrhythmias by blocking HERG channels, which causes longer QT intervals on ECGs. HERG screening is an active measure that involves the systematic testing of compounds to assess their impact on HERG channels. This process helps in early identification and elimination of drugs with potential proarrhythmic effects and ensures a safer pharmaceutical development pathway. Consequently, by identifying and reducing the risks associated with HERG inhibition, this screening method contribute in the well-being of patient and minimize cardiovascular complications related to drug usage.

Market Highlights

HERG Screening Market is expected to grow at a compound annual growth rate (CAGR) of 13.7% from 2024 to 2034

HERG Screening Market is projected to reach USD 7.1 billion over the forecast period, owing to the rising focus on drug safety within the pharmaceutical development sector. The increasing awareness of potential cardiotoxicity risks that are associated with drug compounds is promoting the demand for HERG screening services and technologies. This surge is attributed to the persistent endeavours by pharmaceutical industries to improve drug development methods and adhere to regulatory standards. Additionally, technological innovations in high-throughput screening and automation are significant contributors, which facilitate the effective assessment of compound libraries. Moreover, frequent collaborations between pharmaceutical companies and contract research organizations highlights a strategic change towards outsourcing HERG screening services. This development indicates of a wider industry strategy to improve efficiency while maintaining strict safety protocols. Thus, as the global pharmaceutical ecosystem continues its expansion, HERG screening market will assume an important role in ensuring the safety and efficacy of emerging drug candidates, thereby presenting attractive opportunities for stakeholders in this sector.

Source: Fatpos Global

HERG Screening Market Segmentation

Gene KCNH2 segment will lead due to its important role in transporting positively charged atoms

Based on Type, the HERG Screening Market is segmented into Gene KCNH2, Mutant KCNH2, and Others. The Gene KCNH2 segment will likely dominate the HERG screening market owing to its essential role in the transport of positively charged potassium atoms out of cells. This process is important for the generation and transmission of electrical impulses. Additionally, Gene KCNH2 is responsible for directing the synthesis of potassium channels by providing necessary instructions for their formation. Furthermore, mutations in the KCNH2 gene significantly contribute in the development of cardiac arrhythmias and can even lead to prolonged QT syndrome. Therefore, given the central importance of Gene KCNH2 in regulating the transportation of cellular potassium and its direct impact on cardiac rhythm, Gene KCNH2 will maintain its market dominance. The occurrence of prolonged QT syndrome linked with KCNH2 mutations further highlights the significance of this gene and emphasize its role in shaping the HERG screening market.

Voltage Gated segment will dominate owing to its significance in the functioning of cell

By Ion-Channel, HERG Screening Market is divided into Voltage Gated, Ligand Gated, and Others. The voltage-gated ion segment is expected to lead the market due to its crucial role in cellular function. This segment includes Na+, Ca+, and K+ channels, which are integral components of the voltage-gated ion channel family. These channels control open and closed states based on variations in the potential of cell membrane and impacts the vital cellular activities in neurons, heart muscle, and skeletal muscle cells. The accurate control of ion transit across cell membranes by these channels is fundamental for maintaining essential ionic gradients. Additionally, voltage-gated ion channels are extremely important as therapeutic targets for various medical conditions such as epilepsy and neuropathic pain. The increasing adoption of voltage-gated ion channels in the treatment of these disorders has become a major factor for the growth of this market. This attests to the rising importance of these channels in medical applications, which contributes to the growth and dominance of voltage-gated ion segment.

Market Dynamics

Growth Drivers

Improvements in Technology will Generate Growth Opportunities

Continuous improvements in technology play an essential role in advancing the HERG screening market. High-throughput screening technologies and automated platforms have transformed the environment of drug development, which provided faster and more accurate evaluation of cardiac risks associated with drug candidates. These innovations empower researchers to efficiently evaluate extensive compound libraries, that lead to a significant reduction in time and resources required for screening. Additionally, the incorporation of advanced technologies improves the accuracy of HERG screening methods and also contributes to overall enhancements in drug development workflows. Therefore, this strategic arrangement with regulatory standards ensures compliance and encourage the creation of safer and effective medications, underscoring the significance of technological advancements in the HERG screening market.

Increased Focus on Drug Safety will Lead to Market Expansion

Growing focus on drug safety in the pharmaceutical sector is a significant driving factor for the growth of HERG screening market. Global regulatory agencies are intensifying safety standards and mandating thorough assessments of potential cardiac risks associated with new drug candidates. Thus, pharmaceutical firms are increasingly acknowledging the significance of integrating HERG screening into their preclinical evaluations. This increasing awareness has induced a cultural shift towards active risk management and has encouraged companies to invest in advanced screening methods to ensure the safety of their products. This emphasis aligns with regulatory expectations and has enhanced public health outcomes by eliminating unforeseen cardiovascular complications associated with pharmaceutical use.

Restraints

Industry Growth Could be Hampered by Cost and Resource Intensiveness

HERG screening has plenty of potential to improve medication safety, but due to its expensive and resource-intensive requirements, it is not yet widely adopted. The implementation and maintenance of essential infrastructure, including specialized laboratory setups and modern equipment, requires substantial financial commitments. The involvement of skilled personnel that are proficient in conducting HERG assays further adds to the overall expenses. This resource-intensive nature presents major difficulties for smaller pharmaceutical companies or research institutions that are operating with limited budgets, which restrict their access to HERG screening capabilities. Therefore, striking a balance between the need for comprehensive safety assessments and the economic practicality of HERG screening is a crucial consideration for stakeholders.

Recent Developments

• On 2022, Novartis International AG partnered with Insilico Medicine to develop AI-powered drug discovery platforms, which could potentially impact HERG screening workflows.
• Johnson & Johnson partnered with XtalPi to develop AI-powered platforms for drug discovery and safety assessment, which could indirectly impact HERG screening approaches.
• On 2022, Roche Holding AG announced collaboration with Accenture to develop AI-powered solutions for drug discovery and development, which could potentially impact HERG screening workflows.

• Bristol Myers Squibb announced collaboration with Accenture to develop AI-powered solutions for drug discovery and development, which could potentially impact HERG screening workflows.

• Pfizer Inc. presented data at American Society for Cell Biology (ASCB) meeting on a novel, AI-powered platform for predicting cardiotoxicity, which could indirectly impact HERG screening approaches.

Key Players:

• Charles River Laboratories International, Inc.
• Thermo Fisher Scientific Inc.
• Molecular Devices, LLC
• Eurofins Discovery
• Nanion Technologies GmbH
• QPS Holdings, LLC
• SB Drug Discovery
• Sophion Bioscience A/S
• ChanTest Corporation
• Cyprotex
• Evotec SE
• Apredica
• Shanghai Medicilon Inc.
• B'SYS GmbH
• Acea Biosciences, Inc.
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Regional Analysis

HERG Screening Market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. North America's prominence in the HERG Screening market is due to advanced pharmaceutical industry, strong healthcare infrastructure, and a commitment to research & development. Leading pharmaceutical companies in the region, such as Charles River Laboratories International, Inc. and Covance Inc., are actively integrating HERG screening into their preclinical evaluations, thereby aligning with strict regulatory standards set by the U.S. Food and Drug Administration (FDA). Furthermore, the emphasis on innovation in North America region creates fresh demand for HERG screening technologies. This comprehensive approach highlights the dominance of North America in the HERG Screening market and positions it as a major player in the global landscape.

HERG Screening Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

HERG Screening Market Scope and Segments:

Frequently Asked Questions (FAQ):